BINEX Co., Ltd. (053030.KQ)
KRW 17490.0
(-3.95%)
KRW 17490.0
(-3.95%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.57 Billion KRW | 263.99% |
| 2022 | 1.53 Billion KRW | -96.48% |
| 2021 | 43.56 Billion KRW | -2.14% |
| 2020 | 44.51 Billion KRW | 19334.35% |
| 2019 | 229.05 Million KRW | 0.0% |
| 2018 | - KRW | -100.0% |
| 2017 | 3 Billion KRW | -64.07% |
| 2016 | 8.35 Billion KRW | -60.15% |
| 2015 | 20.95 Billion KRW | 0.0% |
| 2013 | 5.32 Billion KRW | -46.22% |
| 2012 | 9.9 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - KRW | 0.0% |
| 2024 Q1 | 5.3 Billion KRW | 0.0% |
| 2023 Q2 | 1.35 Billion KRW | -13.71% |
| 2023 Q3 | 5.12 Billion KRW | 279.85% |
| 2023 FY | 5.57 Billion KRW | 263.99% |
| 2023 Q4 | 5.57 Billion KRW | 8.76% |
| 2023 Q1 | 1.56 Billion KRW | 2.11% |
| 2022 Q1 | 2.07 Billion KRW | -95.24% |
| 2022 Q4 | 1.53 Billion KRW | -62.37% |
| 2022 Q3 | 4.07 Billion KRW | 96.48% |
| 2022 Q2 | 2.07 Billion KRW | 0.0% |
| 2022 FY | 1.53 Billion KRW | -96.48% |
| 2021 FY | 43.56 Billion KRW | -2.14% |
| 2021 Q3 | 43.17 Billion KRW | 0.91% |
| 2021 Q4 | 43.56 Billion KRW | 0.9% |
| 2021 Q1 | 42.39 Billion KRW | -4.92% |
| 2021 Q2 | 42.78 Billion KRW | 0.91% |
| 2020 Q4 | 44.59 Billion KRW | 1230.9% |
| 2020 FY | 44.51 Billion KRW | 19334.35% |
| 2020 Q3 | 3.35 Billion KRW | -10.67% |
| 2020 Q2 | 3.75 Billion KRW | 1336.76% |
| 2020 Q1 | 261.03 Million KRW | 13.96% |
| 2019 Q2 | 212.36 Million KRW | 0.0% |
| 2019 FY | 229.05 Million KRW | 0.0% |
| 2019 Q4 | 229.05 Million KRW | 34.91% |
| 2019 Q3 | 169.78 Million KRW | -20.05% |
| 2019 Q1 | - KRW | 0.0% |
| 2018 FY | - KRW | -100.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q1 | - KRW | -100.0% |
| 2017 FY | 3 Billion KRW | -64.07% |
| 2017 Q1 | 9.38 Billion KRW | 12.34% |
| 2017 Q2 | 6.73 Billion KRW | -28.25% |
| 2017 Q4 | 3 Billion KRW | 0.0% |
| 2017 Q3 | - KRW | -100.0% |
| 2016 Q2 | 23.6 Billion KRW | 1.41% |
| 2016 FY | 8.35 Billion KRW | -60.15% |
| 2016 Q4 | 8.35 Billion KRW | -65.13% |
| 2016 Q3 | 23.94 Billion KRW | 1.44% |
| 2016 Q1 | 23.27 Billion KRW | 11.09% |
| 2015 Q4 | 20.95 Billion KRW | 0.0% |
| 2015 FY | 20.95 Billion KRW | 0.0% |
| 2014 Q3 | 9.31 Billion KRW | -3.81% |
| 2014 Q1 | 4.95 Billion KRW | -6.92% |
| 2014 Q2 | 9.68 Billion KRW | 95.47% |
| 2013 Q2 | 5.16 Billion KRW | -34.66% |
| 2013 FY | 5.32 Billion KRW | -46.22% |
| 2013 Q4 | 5.32 Billion KRW | 3.15% |
| 2013 Q3 | 5.16 Billion KRW | 0.0% |
| 2013 Q1 | 7.9 Billion KRW | -20.2% |
| 2012 Q4 | 9.9 Billion KRW | 0.0% |
| 2012 FY | 9.9 Billion KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 17.93 Billion KRW | 68.894% |
| iNtRON Biotechnology, Inc. | 258.29 Million KRW | -2059.685% |
| Bioneer Corporation | 12.5 Billion KRW | 55.373% |
| Anterogen.Co.,Ltd. | - KRW | -Infinity% |
| MEDIPOST Co., Ltd. | 6.99 Billion KRW | 20.251% |
| CrystalGenomics, Inc. | 29.88 Billion USD | 81.337% |
| Helixmith Co., Ltd | 151.68 Million KRW | -3577.713% |
| Chabiotech Co.,Ltd. | 95.06 Billion KRW | 94.132% |
| Medy-Tox Inc. | 1.22 Billion KRW | -355.063% |
| Peptron, Inc. | 4.5 Billion KRW | -23.963% |
| Amicogen, Inc. | 70.65 Billion KRW | 92.105% |
| Genexine, Inc. | 22.68 Billion KRW | 75.406% |
| HLB Therapeutics Co.,Ltd. | 1.84 Billion KRW | -203.14% |
| LegoChem Biosciences, Inc. | 528.37 Million KRW | -955.761% |
| ALTEOGEN Inc. | 1.24 Billion KRW | -346.534% |
| PharmaResearch Co., Ltd. | 970.71 Million KRW | -474.663% |
| SillaJen, Inc. | 8.13 Billion KRW | 31.435% |
| JETEMA, Co., Ltd. | 60 Billion KRW | 90.703% |
| OliX Pharmaceuticals,Inc | 35.36 Billion KRW | 84.225% |
| Genomictree Inc. | 97.51 Million KRW | -5620.471% |
| MedPacto, Inc. | 1.68 Billion KRW | -230.678% |
| D&D Pharmatech | 5.12 Billion KRW | -8.939% |
| EASY BIO,Inc. | 30 Billion KRW | 81.405% |
| GI Innovation, Inc. | 2.9 Billion KRW | -92.092% |